UK M&A isn’t recovering evenly. It’s concentrating.

UK M&A isn't recovering evenly. It's concentrating.

A deals recovery is typically characterised by broader participation, improving confidence and rising transaction volumes. The UK market is exhibiting the opposite.

Capital deployed more than doubled from £60bn in H1 2025 to £134.7bn in H1 2026, almost returning to H2 2020 levels. But deal volumes contracted by almost 13%, extending the decline in transaction activity seen since the market peaked in H2 2021.

Deal value is concentrating across most sectors. This suggests a structural shift in how capital is being deployed, consistent with a K-shaped pattern. We see this pattern globally, but it is more pronounced in the UK.

UK Deals value by Sector, H1 2026 vs H1 2025, value and volume

Four sectors stand out as attracting significant deal capital, three of which are driven by advances in AI and technology.

Financial Services: tech-led consolidation

Deal value reached £35.6bn (26% of H1 2026 total deal value), more than doubling from £16.5bn in H1 2025. But investors' objectives have shifted from scale to reinvention, with activity driven by pressure to modernise technology, optimise capital and respond to changing customer expectations.

Recent transactions reflect that shift. Nuveen's £9.6bn acquisition of Schroders and EQT's £2.8bn acquisition of Coller Capital point to continued consolidation across asset management, while Zurich Insurance's £8.1bn acquisition of Beazley shows the same dynamic in insurance. NatWest's £2.7bn acquisition of Evelyn Partners expands its position in UK wealth and advisory, and Standard Life’s £2.0bn acquisition of Aegon UK strengthens its scale in long-term savings and insurance.

We expect this activity to continue. Financial services is entering a period of reinvention, as AI, tokenisation and new digital infrastructure change how firms operate and compete. For boards, that raises practical questions about what they need to own, what they can build and where M&A can get them there faster. Acquisitions and portfolio reshaping will increasingly be used to bring in technology, data and specialist capabilities that would take much longer to build organically.

TMT: AI-enabled investment

TMT deal value increased from £10.3bn to £14.8bn, representing 11% of total UK deal value. Capital continues to flow into AI-enabled software, digital infrastructure, data centres and data platforms, although investors are becoming much more selective about where they see long-term value. Our most recent Global Data Centre Outlook 2026-2050 estimates that US$31.6 trillion could be invested in data centres globally by 2050, with power, policy and data sovereignty shaping where that investment goes and creating new opportunities for markets in the UK.

Recent deals give a good indication of where that conviction sits. The £1bn+ sale of Sedex reflects continued appetite for businesses combining technology, data and growth potential. Nexfibre's £2.0bn acquisition of Substantial Group points to the demand for scalable digital infrastructure, while Bullish's £3.1bn acquisition of Equiniti is another example of significant capital being deployed into technology and data-enabled businesses.

Software is more complicated. The so-called "SaaSpocalypse" accelerated a reassessment of valuations and opened up a much sharper debate about which business models will hold their value as AI develops. Businesses with proprietary data, embedded workflows and high switching costs are generally giving buyers more confidence. Those that are easier to replicate or more exposed to AI substitutions are having to work much harder to make the investment case.

This is not simply a story of more money flowing into technology. As valuations and investment become increasingly concentrated around AI, inevitably, enhanced risks will come with that concentration. It’s no longer a case of whether a business can benefit from AI, but whether its valuation, competitive position and business model remain resilient if expectations change.

Healthcare: innovation-led consolidation

Deal value increased from £2.3bn in H1 2025 to £13.0bn in H1 2026 (10% of total deals value), suggesting that strategic healthcare M&A remains resilient despite wider market uncertainty.

GSK's £8bn acquisition of Nuvalent highlights the continued race among global pharmaceutical companies to secure breakthrough science, innovative therapies and future pipeline growth. Eli Lilly's £5.1bn acquisition of Centessa Pharmaceuticals reinforces this trend and illustrates the premium placed on UK life sciences innovation and high-quality intellectual property.

Capital is becoming progressively specialised. Life sciences private equity, healthcare-focused growth investors and global pharmaceutical companies are directing investment towards differentiated, scalable businesses, while generalist investors remain more selective. Innovation is increasingly driving valuation as well as growth.

Consumer Markets: investor activism

Consumer Markets were the largest contributor to UK deal value, growing fivefold to £39.2bn compared to H1 2025 (29% of total deals value in H1 2026). This was driven largely by two transactions: the £33bn merger of Unilever's food business with McCormick, accounting for around 85% of total sector’s value alone, and Ingredion's £2.7bn acquisition of Tate & Lyle.

Rather than signalling a broad-based recovery in consumer markets, the data shows a small number of activist-driven corporate situations and strategic portfolio disposals. The strategic rationale has centred on portfolio simplification, exemplified by Unilever's decision to refocus on health, beauty and hygiene, while private capital remains comparatively cautious towards the wider sector.

Industrials and Energy: A more challenging backdrop

By contrast, Industrials and Services have remained active but continue to face a difficult UK backdrop of low growth and persistent cost pressures.

Energy, Utilities and Resources has faced geopolitical uncertainty, alongside questions around regulation and long-term policy direction. But strategic capital is still moving where investors have conviction in the long-term opportunity. ENGIE’s £10.5bn acquisition of UK Power Networks is a clear example, bringing significant capital into critical UK energy infrastructure despite the more challenging backdrop.

Capital is shifting towards larger deals

Capital is abundant. Conviction is scarce.

Fewer buyers are competing for fewer assets but with significantly greater intensity. Premium assets continue to command strong valuations, even as broader market multiples remain under pressure.

Capital itself is not the constraint. PwC's Global Private Credit Survey 2026 found that four in five portfolio managers expect allocations to increase over the next 12 months. But rather than translating directly into more transactions, that capital is supporting larger, higher-conviction deals, refinancing and a broader range of investment strategies.

The pressure to reinvent among corporates is growing. That urgency is translating into greater appetite for transformation, but investment committees are demanding greater certainty before deploying capital.

Across the deals processes that we support, the same pattern is visible; differentiated assets generate stronger buyer interest, while weaker processes are becoming harder to execute.

Investors are gravitating towards businesses that command what we call a ‘Concentration Premium’. This is defined by four characteristics: strategic coherence, sustainable differentiation, executable value creation and fitness for the future. For those assets that can demonstrate and evidence a combination of these characteristics, bidder appetite is strong with valuations well above historical multiples.

But concentration also creates risk. When more capital chases the same themes, particularly AI, valuations can run ahead of fundamentals. Buyers need to distinguish genuine competitive advantage from market momentum and be confident the investment case still works if expectations change.

The ‘Concentration Premium’

The concentration of capital is most visible in the largest transactions. The ten biggest UK deals accounted for almost two-thirds of total deal value in H1 2026 across sectors including Consumer Markets, Financial Services, Industrials & Services and Healthcare. What they show is that buyers are still willing to commit significant capital when they have confidence in the asset and a clear strategic rationale for the deal.

Top 10 UK Deals by target, H1 2026

Agentic AI is creating a new valuation divide

The questions already being asked in technology are now being asked much more widely. Boards want to know what agentic AI could mean for their industry, where it will create value, what capabilities they will need and, ultimately, how businesses will make money as it gains traction.

That is starting to change the way buyers look at potential acquisitions. Buying can be a much faster route to technology, talent and proprietary data than building those capabilities internally. But access to AI capability is only one side of the investment case. Buyers also must understand what AI could do to the economics of the business they are acquiring.

Some of the questions are quite fundamental. Could AI open up new revenue streams or put existing ones under pressure? Could it improve margins or change the cost base? Does it make the company’s products more valuable, or easier for somebody else to replicate? And what happens to its competitive position if adoption moves faster than expected?

Much of the value being placed on AI today is based on what it could deliver rather than what it already has. Buyers therefore need to test those expectations carefully and decide how much of that future value they are prepared to pay for today.

These are no longer questions that can be left to the technology diligence team towards the end of a process. They affect the commercial case, valuation and value creation plan. Financial, commercial, technology, cyber, tax, regulatory, operational and integration work increasingly needs to happen in parallel if buyers are going to reach a view quickly and invest with conviction.

Execution can be as valuable as price

Buyers who can move quickly with clear investment theses and funding certainty are increasingly gaining an advantage in competitive processes. Price remains important, but confidence in completion, speed of decision-making and a credible plan for value creation are more likely to determine the outcome.

What winning transactions share:

1.  Quality creates competitive tension – Bidders need comfort on an asset’s differentiation, resilience and scalability, in that order. Assets need to prove out their ability to mitigate risk of market headwinds and generate above market growth. For sellers, being able to prove that case early can make a real difference to buyer confidence and competitive tension.
2. Certainty can beat price – The winning offer is not always the highest one. Sellers increasingly value certainty of execution alongside headline price. This gives well-prepared bidders an advantage when they can remove risk early and demonstrate confidence of completion.
3. Capital structure is a competitive advantage – Private credit-backed funding structures can remove execution risk and provide greater certainty than traditional syndicated financing, allowing buyers to move more quickly and with fewer conditions.
4. The investment thesis must address agentic AI – Buyers need to understand how AI will impact a target's products, customers, operating model, competitive position and long-term value creation potential. Without a credible AI thesis, it becomes significantly harder to assess future earnings and invest with conviction.
5.  Judgement decides outcomes – AI can compress diligence timelines and improve information processing, but investment decisions continue to depend on experience, sector expertise and commercial judgement. The advantage comes from combining AI-enabled data analysis with informed human judgement.
   

A new discipline for deal makers

As capital becomes more concentrated, generalist investors are giving way to sector specialists with deeper expertise, stronger conviction and more focused investment theses. Strategic corporates are following the same path, using acquisitions to accelerate transformation, build resilience, and secure differentiated capabilities rather than simply add scale.

Private equity provides the clearest example. Longer holding periods and subdued exit activity have increased the focus on refinancing and transforming portfolio companies, while private credit is giving sponsors greater flexibility and certainty over how those strategies are funded.

The implications extend well beyond private equity. For corporate acquirers, strategy, financing, operations, technology, tax and value creation can no longer be assessed sequentially. They need to be considered in parallel, allowing boards to move faster without sacrificing confidence.

The five disciplines of winning bids

How bidders can close and extract value from a deal today

Looking ahead: the next UK M&A horizon

We expect concentration to persist, AI disruption to accelerate and the gap between the best-positioned buyers and the rest to widen.

In summary

Capital is not the constraint in this market. The bigger question is where investors are prepared to deploy it. With a relatively small pool of high-quality assets attracting much of the investment, success will depend increasingly on finding the right opportunities, having conviction in the investment case and being able to execute.

There is also a compounding effect. Assets that attract strong initial interest tend to generate greater competitive tension, giving owners more choice over timing, structure and counterparties. Buyers develop an advantage too: the more they specialise, the deeper their sector knowledge becomes and the better placed they are to identify and execute the next opportunity. Over time, that could make the market more, rather than less, concentrated.

The response will not be the same for everyone. Private equity firms will need to decide where they genuinely have the sector expertise and value creation capabilities to compete. Corporate boards face a different question: which businesses and capabilities will matter to their strategy in five or ten years, and which parts of the portfolio no longer fit? Lenders will increasingly need to distinguish between an attractive transaction and an investment case that can actually be delivered.

What is common to all three is the danger of waiting. A broad recovery in deal volumes may come, but waiting for it risks missing the assets and capabilities that could shape future growth.

The future of UK M&A will belong to those with the clearest conviction about where value will be created, and the confidence to act before consensus forms.